Search - tctmd.com

Displaying 221 - 240 of 642

Sort: Relevancy | Date

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

L.A. McKeown

May 03, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

Presentation

Incident MI and Very Late Stent Thrombosis in Outpatients With Stable CAD

April 25, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Presentation JIM 2017

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

Presenter: Giuseppe Musumeci

February 09, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

Advertisement

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

Incident MI and Very Late Stent Thrombosis in Outpatients With Stable CAD

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

The Left Main Debate: What Does it Mean for the Future of Intervention?

Absorb BVS Use Restricted in Europe

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content